Functional cure for hepatitis B!

A few days ago, VBI Vaccines announced that the second phase 2a/2b clinical trial of VBI-2601 (BRII-179), a novel recombinant protein immunotherapy jointly developed with Brii Biosciences, has completed the first patient dosing

Hepatitis B is one of the most significant infectious disease threats in the world, with more than 290 million people infected globally

VBI-2601 is an innovative recombinant protein-based immunotherapy designed to enhance B- and T-cell immune responses based on a VBI-based prophylactic HBV vaccine candidate

Phase 2a of this randomized, double-blind, placebo-controlled Phase 2a/2b clinical trial is expected to enroll 120 patients, with the primary endpoint being the percentage of patients with HBsAg clearance at the end of treatment; 480 patients will be re-enrolled in Phase 2b, the primary endpoint Percentage of patients who achieved functional cure (defined as undetectable HBsAg and observed sustained suppression of HBV DNA)

References:

[1] VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio.

https:// part-of-expansion-of-clinical-collaboration-with-brii-bio/

(Original abridged)